Table 1.
Baseline Characteristics of Study Participants
| Characteristic | Value |
|---|---|
| Sex, No. (%) | |
| Male | 20 (90.9) |
| Female | 2 (9.9) |
| Age, y | |
| Median (IQR) | 51 (46–54) |
| Range | 38–61 |
| Race, No. (%) | |
| African American | 9 (40.9) |
| Caucasian | 10 (45.5) |
| Multiple race | 1 (4.5) |
| Unknown | 2 (9.1) |
| Antiretroviral drug regimen at study entry, No. (%) | |
| NNRTI | 1 (4.5) |
| PI | 0 (0) |
| PI/INSTI | 1 (4.5) |
| INSTI | 20 (90.9) |
| Duration of HIV suppression on ART at study entry, y | |
| Median (IQR) | 7.7 (3.1–11.1) |
| Range | 2.08–15.9 |
| CD4+ T-cell count at study entry, cells/mm3 | |
| Median (IQR) | 767 (591–946) |
| Range | 466–1778 |
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.